Articles tagged with Alzheimer Disease
Researchers found that using nonsteroidal anti-inflammatory drugs (NSAIDs) may help slow the progression of Alzheimer's disease. However, data suggests that low-dose aspirin use does not provide a significant protective effect against developing Alzheimer's.
Researchers found that immunization can stimulate the immune system to combat prion disease, which affects humans and animals. The study suggests that vaccination could be an effective therapy for prion diseases like Creutzfeldt-Jakob disease and Alzheimer's disease.
Researchers found that increasing neprilysin levels decreased amyloid deposition and reduced plaque load in transgenic mice. Astrocytes also degraded beta-amyloid peptides, suggesting a new target for AD therapies.
A recent pilot study published in the American Journal of Geriatric Psychiatry found that high-dose vitamins can reduce homocysteine levels in individuals with mild to moderate Alzheimer's disease. The multicenter trial, known as Vital, aims to determine if these vitamins can slow the progression of the disease. Researchers are optimis...
David M. Holtzman and Ashley I. Bush have been awarded the 2003 Potamkin Prize for their work on amyloid accumulation and oxidation in Alzheimer's disease. Their research has provided essential basic foundation for understanding how to treat the pathology related to amyloid accumulation.
Researchers at Columbia University have found that astrocytes can degrade beta-amyloid proteins, a key component of Alzheimer's plaques, suggesting potential therapeutic targets for the disease. The study suggests activating astrocyte activity may be beneficial in reducing plaque buildup and improving treatment outcomes.
A research team found a fly mutation that causes early cell death and neural degeneration in the brain, similar to human neurodegenerative diseases. The mutation is associated with protein aggregates found in human Alzheimer's patients.
Research suggests that high intake of unsaturated fats may be protective against AD, while saturated and trans-unsaturated fats increase risk. Additionally, studies found no association between antioxidant vitamin intake and reduced AD risk.
A decade-long analysis of 500 families with Alzheimer's Disease suggests a future of early prediction and prevention. The findings lead to a new vision of medical care, applicable not only to Alzheimer's but also to other genetic disorders.
Researchers discovered that many nonagenarians (people 90-99 years old) are free of Alzheimer's disease or dementia, with some performing in the superior range on cognitive tests. Mild cognitive impairment (MCI) also exists in this age group, but features similar characteristics to those seen in younger individuals.
The study reveals that protein components in the post-synaptic density (PSD) move together in response to neural activity, with a significant percentage undergoing up-and-down regulation. The findings also suggest a high rate of PSD remodeling, with neurons replacing its content multiple times a day.
A study published in the Journal of Neuroscience found that Alzheimer's patients who scored well on memory tests show distinct compensatory brain activity. This activity was observed in the right frontal and temporoparietal areas, and was associated with improved performance on semantic and episodic memory tasks.
A new mouse genetic model exhibits a non-lethal form of spongiform brain disease, characterized by fluid-filled vacuoles and tissue degeneration. The mice lack the same motor coordination problems as affected cattle and are not contagious.
A new report by the London School of Economics predicts a 66% rise in people with cognitive impairment, leading to increased long-term care costs. The study suggests that demand for long-term care will rise faster among those with cognitive impairment.
A study found that injecting beta-amyloid binding agents into the bloodstream reduced brain plaques and amyloid protein levels in mice with Alzheimer's disease. The researchers suggest this approach as an initial step towards developing targeted drugs with fewer side effects.
A meta-analysis of 29 trials found that cholinesterase inhibitors improved behavioral and functional status in patients with mild to moderate Alzheimer's disease. The study suggests potential benefits for improving quality of life and reducing caregiver burdens, but long-term research is needed to confirm these findings.
Experts emphasize that clinicians can improve quality of life for Alzheimer's patients by following guidelines and utilizing available resources. The number of people with Alzheimer's is expected to swell from 4 million in 2002 to 14 million by 2050, highlighting the need for effective care options.
The new center will be equipped with a high-field MRI/MR spectroscopy system, allowing for early detection and monitoring of Alzheimer's disease. The center will also conduct research on newest drug treatments for neurodegenerative disorders.
The study found that median survival times for Alzheimer's patients vary significantly depending on the age at diagnosis, ranging from nearly 9 years for those diagnosed at 65 to approximately 3 years for those diagnosed at 90. Additionally, researchers reported an average time of 2.8 years between symptom onset and diagnosis.
Researchers found that incorporating standard appliances, real plants, and natural materials can create a comfortable environment for residents. The study recommends varying counter heights and using side-by-side refrigerators to accommodate different needs.
Researchers have developed a new diagnostic tool using PET scans to detect Alzheimer's disease more accurately. By analyzing brain activity, the scans can identify changes that occur before patients themselves may recognize problems.
A study using female rats found that long-term estrogen replacement therapy impaired memory performance, especially when combined with chronic brain inflammation. This effect is analogous to the observed decline in cognitive function in postmenopausal women with Alzheimer's disease who receive continuous estrogen therapy.
A recent study suggests that shunting cerebrospinal fluid may help slow cognitive decline in patients with Alzheimer's disease. In a small, controlled trial, patients with Alzheimer's and normal pressure hydrocephalus experienced relative stability compared to those without shunts.
A controlled study found that memory training improved recalling people's names among participants with mild to minimal Alzheimer's Disease. Those who were more aware of their failing memories showed the most improvement.
Researchers discussed potential breakthroughs in understanding Alzheimer's disease, with one expert suggesting genetic testing could aid early diagnosis. Another speaker addressed the need for public education on vaccine risks and the challenges of bioterrorism preparedness.
The Lancet Neurology recently published a series of articles discussing the latest evidence on Alzheimer's disease, including preventative anti-inflammatory clinical trials and the role of secretases in producing amyloid-beta peptide. Researchers argue that these approaches hold promise for preventing or slowing the onset of the disease.
A recent study by Rensselaer researchers found that exposure to blue LED lighting can delay the decline of body temperatures in Alzheimer's patients, leading to better sleep. The study also showed increased activity during daylight hours for two patients who wore wrist activity monitors.
Research suggests that long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce the risk of Alzheimer's disease by up to 45% if started before the onset of dementia. Aspirin compounds and other medications showed similar protective effects, while recent or late use offered little protection.
A study published in Biochemistry found significant alterations in white matter tissue of Alzheimer's patients, suggesting a potential initiating step for the disease. White matter degeneration may be caused by a disease of oligodendrocytes, leading to axon damage and cognitive impairments.
Researchers found that beta-secretase activity is increased in Alzheimer's diseased brains, specifically in temporal and frontal cortex. This increase persists throughout the duration of the illness, making BACE a promising target for treatment, even late in the disease.
A study has identified genetic markers that can help guide clinical trials for anti-Alzheimer drugs, potentially leading to the development of a more manageable pool of individuals at high risk. These markers may allow researchers to winnow down the general population and focus on those with relatively higher risk for Alzheimer's disease.
Researchers have discovered a new anti-inflammatory drug, NCX-2216, that effectively removes excess amyloid protein from the brains of mice with Alzheimer's-like memory disorders. The nitro-NSAID also activates immune cells called microglia, which may help remove amyloid before it hardens into toxic plaques.
A meta-analysis of 31 studies found the California Verbal Learning Test to be the most accurate predictor of Alzheimer's type dementia. Researchers also discovered that odor identification tests can identify preclinical Alzheimer's in individuals with the ApoE gene more effectively than neuroimaging measures.
Researchers at The Wistar Institute have discovered a link between neurofibromatosis and Alzheimer's disease, with the shared protein kinesin-1 playing a pivotal role in protein trafficking. This finding opens new avenues for investigation into both diseases, providing insights into vital cellular processes.
A study found that consuming more calories and fats may be linked to a higher risk of developing Alzheimer's disease. The research, published in the Archives of Neurology, followed 980 elderly individuals for an average of four years and recorded their calorie intake.
A seven-year study found that elderly individuals with depressive symptoms were more likely to develop Alzheimer's disease and experienced rapid cognitive decline. The risk of developing AD increased by 20% for each additional symptom.
Researchers have created a prototype, Activity Compass, that uses sensors and GPS to monitor daily routines and provide prompts. The device aims to help patients maintain independence and reduce emotional burnout on caregivers.
Chicago researchers awarded $9 million NIH grant to investigate the impact of lifestyle experiences on cognitive function and Alzheimer's disease. The study aims to understand how cognitively stimulating activities can increase neural reserve and reduce the likelihood of memory loss and other clinical signs of Alzheimer's.
Researchers found that Alzheimer's drug donepezil improved pilots' ability to retain complex training in a flight simulator test. The study used 18 pilots aged 52 and tested the theory that aging affects cognitive abilities due to loss of acetylcholine.
A population-based study suggests that a diet high in foods containing vitamin E may help protect against Alzheimer's disease, with the most significant protective effect found among those with the lowest dietary vitamin E intake. The study also found no association between vitamin E supplements and reduced risk of AD.
Researchers at Georgetown University Medical Center have discovered a key link between high cholesterol and the development of Alzheimer's disease. Elevated cholesterol levels increase the production of beta amyloid protein, leading to brain cell death and characteristic plaques found in Alzheimer's brains.
A simple urine test can predict Alzheimer's disease by detecting increased brain oxidative damage in the form of isoprostanes in urine. The test may help doctors diagnose the disease earlier, allowing for slower progression and better treatment response.
A study reveals that Alzheimer's plaques can cause a flood of negative ions to drain healthy cells of their charge, leading to cell death. Researchers found that certain drugs can reverse this effect, suggesting a new direction for therapy development.
Alzheimer's disease prevalence is projected to double by 2050 due to a growing population of older adults. A new report suggests that even with significant treatment breakthroughs, the burden on healthcare systems will increase threefold.
Researchers have discovered that MRI scans can identify individuals at high risk of developing Alzheimer's disease decades in advance. The study used postmortem brain scans to show that shrinkage of the hippocampus, a key region affected by the disease, occurs early on.
A new drug, CPHPC, has been developed to remove a blood protein linked to amyloidosis, a disorder that claims 1,000 UK lives annually. The drug blocks SAP proteins from sticking to amyloid fibers, speeding up their removal and offering potential treatment for Alzheimer's and diabetes.
A study by Dr. Anne B. Newman found that people with cardiovascular disease have a 30% increased risk of dementia, primarily due to vascular dementia caused by insufficient blood flow to the brain. Preventing cardiovascular disease may be an effective measure for preventing dementia in older adults.
Researchers found that tau protein is necessary for beta-amyloid to cause brain cell degeneration in Alzheimer's disease. Tau-depleted neurons showed rapid microtubule turnover, suggesting potential resistance to neurodegeneration.
Scientists have successfully reproduced Hirano bodies in the lab using a novel method, opening doors to new studies of these structures. The discovery suggests that Hirano bodies may play a role in various diseases, including Alzheimer's, and could provide a key tool for investigations.
A study published in the American Journal of Clinical Nutrition found that high levels of homocysteine correlate with lower cognitive test scores and decreased cognitive function in the elderly. Higher plasma concentrations of folate and B-12 were associated with improved cognitive performance.
Researchers found that statin use was associated with a 79% reduced risk of developing Alzheimer's disease, regardless of ethnicity or apoE gene variant. The study also showed no difference between natural and synthetic statins in reducing the risk.
The Lancet Neurology aims to report the most important advances in neurology, predicting risk of neurological conditions through genetics and imaging. Experimental therapies like gene therapy and stem cells offer potential for treating neurological disorders.
New drug targets have been identified by Buck Institute researcher Vivian Hook, Ph.D., that could help treat Alzheimer's Disease. The targets participate in producing the toxic beta-amyloid peptide, which accumulates to form plaques in the brain.
A new study found that galantamine improves cognition and daily living activities in patients with vascular dementia. The medication was also shown to reduce symptoms of behavioural changes, providing a potential treatment option for patients with limited pharmacological help.
Researchers at the University of South Florida found that individuals with the E4 type of apolipoprotein E (APOE) gene experience worse recovery of general memory function after brain injury. The study, which genotyped 110 head-injured patients, suggests common cellular responses in both traumatic brain injury and Alzheimer's disease.
A study found that participants with Alzheimer's disease showed greater discrepancies in cognitive skills, particularly in visual and verbal tests. The research suggests that non-invasive cognitive tests could detect early signs of the disease.
Researchers investigate subtle cognitive changes and brain asymmetry as potential precursors to Alzheimer's Disease, using neuropsychological tests to track changes in cognition over time. The studies aim to identify individuals at high risk of developing the disease, enabling earlier intervention and minimizing brain damage.
In a three-month study, ARICEPT significantly improved cognition and daily living skills compared to Reminyl. The treatment was better tolerated by patients taking ARICEPT, with fewer gastrointestinal adverse events.
Researchers found that statins block the vasoconstrictive effects of A-beta protein and have anti-inflammatory properties that may protect against dementia. Statin treatment has been linked to a reduced risk of developing Alzheimer's disease in populations studied.
A team of researchers has discovered that the medial superior temporal area (MST) acts as both a compass and biological global positioning system, providing mental maps to help understand location and movement. This finding helps explain why people with Alzheimer's disease struggle to navigate their environment.